Bausch + Lomb (BLCO) Competitors

Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.

Which has more volatility and risk, BLCO or ZBH?

Bausch + Lomb has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

Does the media favor BLCO or ZBH?

In the previous week, Zimmer Biomet had 9 more articles in the media than Bausch + Lomb. MarketBeat recorded 15 mentions for Zimmer Biomet and 6 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 0.77 beat Bausch + Lomb's score of 0.41 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zimmer Biomet	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BLCO or ZBH more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Bausch + Lomb's net margin of -7.86%. Zimmer Biomet's return on equity of 12.95% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-7.86%	3.17%	1.59%
Zimmer Biomet	14.27%	12.95%	7.55%

Do analysts prefer BLCO or ZBH?

Bausch + Lomb currently has a consensus price target of $20.58, indicating a potential upside of 14.35%. Zimmer Biomet has a consensus price target of $123.33, indicating a potential upside of 15.14%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.31
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.25

Do insiders and institutionals believe in BLCO or ZBH?

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.2% of Bausch + Lomb shares are held by company insiders. Comparatively, 1.0% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer BLCO or ZBH?

Zimmer Biomet received 866 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 67.16% of users gave Zimmer Biomet an outperform vote while only 40.96% of users gave Bausch + Lomb an outperform vote.

Company	Underperform	Outperform
Bausch + Lomb	Outperform Votes 34 40.96%	Underperform Votes 49 59.04%
Zimmer Biomet	Outperform Votes 900 67.16%	Underperform Votes 440 32.84%

Which has preferable valuation & earnings, BLCO or ZBH?

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$4.68B	1.35	-$260M	-$1.05	-17.14
Zimmer Biomet	$7.60B	2.81	$1.02B	$5.26	20.37

Summary

Zimmer Biomet beats Bausch + Lomb on 17 of the 18 factors compared between the two stocks.